Reena Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Reena Thomas has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Gordon Li
Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA
2 shared publications Hannes Vogel
Department of Pathology, Division of Neuro Pathology, Stanford University, Stanford, California
2 shared publications- Ivan Lopez
Stanford University School of Medicine, Stanford, USA
2 shared publications Seema Nagpal
Department of Neurology, Division of Neuro Oncology, Stanford, California
2 shared publications- Aarohi Bhargava-Shah
Stanford University School of Medicine
1 shared publication - Adela Wu
Department of Neurosurgery, Stanford University, Stanford, California, USA
1 shared publication
Latest Publications
- 1 January 2024
- Published by Springer Nature
- p. 253-262
Navigating Neuro-Oncology Care: Addressing Health Disparities in Access and Outcomes
- 1 January 2024
- Published by Springer Nature
- p. 253-262
Navigating Neuro-Oncology Care: Addressing Health Disparities in Access and Outcomes
- 1 January 2024
- Published by Springer Nature
- p. 415-422
Training and Education
- Open Access
Data-driven extraction of unstructured electronic health records to evaluate glioblastoma treatment patterns
Background Data on lines of therapy (LOTs) for cancer treatment is important for clinical oncology research, but LOTs are not explicitly recorded in EHRs. We present an efficient approach for clinical data abstraction and a flexible algorithm to derive LOTs from EHR-based medication data on patients with glioblastoma (GBM). Methods Non-clinicians were trained to abstract the diagnosis of GBM from EHRs, and their accuracy was compared to abstraction performed by clinicians. The resulting data was used to build a cohort of patients with confirmed GBM diagnosis. An algorithm was developed to derive LOTs using structured medication data, accounting for the addition and discontinuation of therapies and drug class. Descriptive statistics were calculated and time-to-next-treatment analysis was performed using the Kaplan-Meier method. Results Treating clinicians as the gold standard, non-clinicians abstracted GBM diagnosis with sensitivity 0.98, specificity 1.00, PPV 1.00, and NPV 0.90, suggesting that non-clinician abstraction of GBM diagnosis was comparable to clinician abstraction. Out of 693 patients with a confirmed diagnosis of GBM, 246 patients contained structured information about the types of medications received. Of those, 165 (67.1%) received a first-line therapy (1L) of temozolomide, and the median time-to-next-treatment from the start of 1L was 179 days. Conclusions We also developed a flexible, interpretable, and easy-to-implement algorithm to derive LOTs given EHR data on medication orders and administrations that can be used to create high-quality datasets for outcomes research. We also showed that the cost of chart abstraction can be reduced by training non-clinicians instead of clinicians. Importance of the study This study proposes an efficient and accurate method to extract unstructured data from electronic health records (EHRs) for cancer outcomes research. The study addresses the limitations of manual abstraction of unstructured clinical data and presents a reproducible, low-cost workflow for clinical data abstraction and a flexible algorithm to derive lines of therapy (LOTs) from EHR-based structured medication data. The LOT data was used to conduct a descriptive treatment pattern analysis and a time-to-next-treatment analysis to demonstrate how EHR-derived unstructured data can be transformed to answer diverse clinical research questions. The study also investigates the feasibility of training non-clinicians to perform abstraction of GBM data, demonstrating that with detailed explanations of clinical documentation, best practices for chart review, and quantitative evaluation of abstraction performance, similar data quality to abstraction performed by clinicians can be achieved. The findings of this study have important implications for improving cancer outcomes research and facilitating the analysis of EHR-derived treatment data.
Open AccessData-driven extraction of unstructured electronic health records to evaluate glioblastoma treatment patterns
Background Data on lines of therapy (LOTs) for cancer treatment is important for clinical oncology research, but LOTs are not explicitly recorded in EHRs. We present an efficient approach for clinical data abstraction and a flexible algorithm to derive LOTs from EHR-based medication data on patients with glioblastoma (GBM). Methods Non-clinicians were trained to abstract the diagnosis of GBM from EHRs, and their accuracy was compared to abstraction performed by clinicians. The resulting data was used to build a cohort of patients with confirmed GBM diagnosis. An algorithm was developed to derive LOTs using structured medication data, accounting for the addition and discontinuation of therapies and drug class. Descriptive statistics were calculated and time-to-next-treatment analysis was performed using the Kaplan-Meier method. Results Treating clinicians as the gold standard, non-clinicians abstracted GBM diagnosis with sensitivity 0.98, specificity 1.00, PPV 1.00, and NPV 0.90, suggesting that non-clinician abstraction of GBM diagnosis was comparable to clinician abstraction. Out of 693 patients with a confirmed diagnosis of GBM, 246 patients contained structured information about the types of medications received. Of those, 165 (67.1%) received a first-line therapy (1L) of temozolomide, and the median time-to-next-treatment from the start of 1L was 179 days. Conclusions We also developed a flexible, interpretable, and easy-to-implement algorithm to derive LOTs given EHR data on medication orders and administrations that can be used to create high-quality datasets for outcomes research. We also showed that the cost of chart abstraction can be reduced by training non-clinicians instead of clinicians. Importance of the study This study proposes an efficient and accurate method to extract unstructured data from electronic health records (EHRs) for cancer outcomes research. The study addresses the limitations of manual abstraction of unstructured clinical data and presents a reproducible, low-cost workflow for clinical data abstraction and a flexible algorithm to derive lines of therapy (LOTs) from EHR-based structured medication data. The LOT data was used to conduct a descriptive treatment pattern analysis and a time-to-next-treatment analysis to demonstrate how EHR-derived unstructured data can be transformed to answer diverse clinical research questions. The study also investigates the feasibility of training non-clinicians to perform abstraction of GBM data, demonstrating that with detailed explanations of clinical documentation, best practices for chart review, and quantitative evaluation of abstraction performance, similar data quality to abstraction performed by clinicians can be achieved. The findings of this study have important implications for improving cancer outcomes research and facilitating the analysis of EHR-derived treatment data.
- Open Access
Modifiers of and Disparities in Palliative and Supportive Care Timing and Utilization among Neurosurgical Patients with Malignant Central Nervous System Tumors
Patients with primary or secondary central nervous system (CNS) malignancies benefit from utilization of palliative care (PC) in addition to other supportive services, such as home health and social work. Guidelines propose early initiation of PC for patients with advanced cancers. We analyzed a cohort of privately insured patients with malignant brain or spinal tumors derived from the Optum Clinformatics Datamart Database to investigate health disparities in access to and utilization of supportive services. We introduce a novel construct, “provider patient racial diversity index” (provider pRDI), which is a measure of the proportion of non-white minority patients a provider encounters to approximate a provider’s patient demographics and suggest a provider’s cultural sensitivity and exposure to diversity. Our analysis demonstrates low rates of PC, home health, and social work services among racial minority patients. Notably, Hispanic patients had low likelihood of engaging with all three categories of supportive services. However, patients who saw providers categorized into high provider pRDI (categories II and III) were increasingly more likely to interface with supportive care services and at an earlier point in their disease courses. This study suggests that prospective studies that examine potential interventions at the provider level, including diversity training, are needed.
Open AccessModifiers of and Disparities in Palliative and Supportive Care Timing and Utilization among Neurosurgical Patients with Malignant Central Nervous System Tumors
Patients with primary or secondary central nervous system (CNS) malignancies benefit from utilization of palliative care (PC) in addition to other supportive services, such as home health and social work. Guidelines propose early initiation of PC for patients with advanced cancers. We analyzed a cohort of privately insured patients with malignant brain or spinal tumors derived from the Optum Clinformatics Datamart Database to investigate health disparities in access to and utilization of supportive services. We introduce a novel construct, “provider patient racial diversity index” (provider pRDI), which is a measure of the proportion of non-white minority patients a provider encounters to approximate a provider’s patient demographics and suggest a provider’s cultural sensitivity and exposure to diversity. Our analysis demonstrates low rates of PC, home health, and social work services among racial minority patients. Notably, Hispanic patients had low likelihood of engaging with all three categories of supportive services. However, patients who saw providers categorized into high provider pRDI (categories II and III) were increasingly more likely to interface with supportive care services and at an earlier point in their disease courses. This study suggests that prospective studies that examine potential interventions at the provider level, including diversity training, are needed.
- 11 March 2021
- Published by SAGE Publications in The Neurohospitalist
- Vol. 12 (1) , 74-79
Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy
Axicabtagene ciloleucel (AC) is an FDA-approved anti-CD19 autologous chimeric antigen receptor T-cell (CAR-T) therapy for refractory diffuse large B cell lymphoma (DLBCL). While its efficacy in DLBCL has been promising, neurotoxicity remains a significant concern. We present a case of a 22-year-old woman with chemotherapy-refractory DLBCL who exhibited Grade IV neurotoxicity in the setting of sepsis, after undergoing AC infusion. Despite prophylactic levetiracetam given per guidelines,1,2 she experienced a precipitous mental status decline on post-infusion day 8 (D8) followed by hypoxic respiratory failure in the setting of clinical status epilepticus on D11 and nonconvulsive status epilepticus (NCSE) on D18. While neuroimaging was unremarkable, EEG demonstrated diffuse slowing and 2.5–3 Hz generalized periodic discharges consistent with NCSE. Seizures were initially refractory to lorazepam, increasing doses of levetiracetam, and phenobarbital, requiring a midazolam drip titrated to 50–70% burst suppression for resolution. Methylprednisolone and tocilizumab were used to treat neurotoxicity and cytokine release syndrome, respectively. Empiric antibiotics were used for sepsis. After cessation of sedatives on D19, mental status improved to near baseline. PET/CT just prior to discharge showed a complete response of the DLBCL (Deauville 3). She was discharged on D37 with no further seizure activity. Unfortunately, a 3-month interval PET/CT demonstrated disease progression which continued through salvage pembrolizumab eventually leading to death 1.2 years post-CAR-T infusion. This case illustrates the clinical management challenges of a complex and rare neurotoxic side effect of CAR-T cell therapy, namely NCSE following status epilepticus.
- 11 March 2021
- Published by SAGE Publications in The Neurohospitalist
- Vol. 12 (1) , 74-79
Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy
Axicabtagene ciloleucel (AC) is an FDA-approved anti-CD19 autologous chimeric antigen receptor T-cell (CAR-T) therapy for refractory diffuse large B cell lymphoma (DLBCL). While its efficacy in DLBCL has been promising, neurotoxicity remains a significant concern. We present a case of a 22-year-old woman with chemotherapy-refractory DLBCL who exhibited Grade IV neurotoxicity in the setting of sepsis, after undergoing AC infusion. Despite prophylactic levetiracetam given per guidelines,1,2 she experienced a precipitous mental status decline on post-infusion day 8 (D8) followed by hypoxic respiratory failure in the setting of clinical status epilepticus on D11 and nonconvulsive status epilepticus (NCSE) on D18. While neuroimaging was unremarkable, EEG demonstrated diffuse slowing and 2.5–3 Hz generalized periodic discharges consistent with NCSE. Seizures were initially refractory to lorazepam, increasing doses of levetiracetam, and phenobarbital, requiring a midazolam drip titrated to 50–70% burst suppression for resolution. Methylprednisolone and tocilizumab were used to treat neurotoxicity and cytokine release syndrome, respectively. Empiric antibiotics were used for sepsis. After cessation of sedatives on D19, mental status improved to near baseline. PET/CT just prior to discharge showed a complete response of the DLBCL (Deauville 3). She was discharged on D37 with no further seizure activity. Unfortunately, a 3-month interval PET/CT demonstrated disease progression which continued through salvage pembrolizumab eventually leading to death 1.2 years post-CAR-T infusion. This case illustrates the clinical management challenges of a complex and rare neurotoxic side effect of CAR-T cell therapy, namely NCSE following status epilepticus.
- 19 September 2019
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (23) , 6948-6957
Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma
Purpose: Preclinical studies have demonstrated that postirradiation tumor revascularization is dependent on a stromal cell–derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4)-driven process in which myeloid cells are recruited from bone marrow. Blocking this axis results in survival improvement in preclinical models of solid tumors, including glioblastoma (GBM). We conducted a phase I/II study to determine the safety and efficacy of Macrophage Exclusion after Radiation Therapy (MERT) using the reversible CXCR4 inhibitor plerixafor in patients with newly diagnosed glioblastoma. Patients and Methods: We enrolled nine patients in the phase I study and an additional 20 patients in phase II using a modified toxicity probability interval (mTPI) design. Plerixafor was continuously infused intravenously via a peripherally inserted central catheter (PICC) line for 4 consecutive weeks beginning at day 35 of conventional treatment with concurrent chemoradiation. Blood serum samples were obtained for pharmacokinetic analysis. Additional studies included relative cerebral blood volume (rCBV) analysis using MRI and histopathology analysis of recurrent tumors. Results: Plerixafor was well tolerated with no drug-attributable grade 3 toxicities observed. At the maximum dose of 400 μg/kg/day, biomarker analysis found suprathreshold plerixafor serum levels and an increase in plasma SDF-1 levels. Median overall survival was 21.3 months [95% confidence interval (CI), 15.9–NA] with a progression-free survival of 14.5 months (95% CI, 11.9–NA). MRI and histopathology support the mechanism of action to inhibit postirradiation tumor revascularization. Conclusions: Infusion of the CXCR4 inhibitor plerixafor was well tolerated as an adjunct to standard chemoirradiation in patients with newly diagnosed GBM and improves local control of tumor recurrences.
- 19 September 2019
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (23) , 6948-6957
Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma
Purpose: Preclinical studies have demonstrated that postirradiation tumor revascularization is dependent on a stromal cell–derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4)-driven process in which myeloid cells are recruited from bone marrow. Blocking this axis results in survival improvement in preclinical models of solid tumors, including glioblastoma (GBM). We conducted a phase I/II study to determine the safety and efficacy of Macrophage Exclusion after Radiation Therapy (MERT) using the reversible CXCR4 inhibitor plerixafor in patients with newly diagnosed glioblastoma. Patients and Methods: We enrolled nine patients in the phase I study and an additional 20 patients in phase II using a modified toxicity probability interval (mTPI) design. Plerixafor was continuously infused intravenously via a peripherally inserted central catheter (PICC) line for 4 consecutive weeks beginning at day 35 of conventional treatment with concurrent chemoradiation. Blood serum samples were obtained for pharmacokinetic analysis. Additional studies included relative cerebral blood volume (rCBV) analysis using MRI and histopathology analysis of recurrent tumors. Results: Plerixafor was well tolerated with no drug-attributable grade 3 toxicities observed. At the maximum dose of 400 μg/kg/day, biomarker analysis found suprathreshold plerixafor serum levels and an increase in plasma SDF-1 levels. Median overall survival was 21.3 months [95% confidence interval (CI), 15.9–NA] with a progression-free survival of 14.5 months (95% CI, 11.9–NA). MRI and histopathology support the mechanism of action to inhibit postirradiation tumor revascularization. Conclusions: Infusion of the CXCR4 inhibitor plerixafor was well tolerated as an adjunct to standard chemoirradiation in patients with newly diagnosed GBM and improves local control of tumor recurrences.
- 22 November 2015
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 3 (4) , 268-271
Response of metastatic glioma to vemurafenib
Extraneural metastatic disease of glioma is rare and poses unique therapeutic challenges. Increasingly, the ability to sequence genetic alterations in tumors has allowed for the identification of common oncogenic signatures such as the activating BRAFV600E mutation and may be useful in therapeutic decision making. We report two patients with widespread aggressive gliomas whose tumors were found to express the BRAFV600E mutation and then responded robustly albeit transiently when exposed to vemurafenib. Although both patients succumbed to their disease, our results suggest that targeting BRAF might be appropriate for patients with aggressive gliomas that express this mutation.
- 22 November 2015
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 3 (4) , 268-271
Response of metastatic glioma to vemurafenib
Extraneural metastatic disease of glioma is rare and poses unique therapeutic challenges. Increasingly, the ability to sequence genetic alterations in tumors has allowed for the identification of common oncogenic signatures such as the activating BRAFV600E mutation and may be useful in therapeutic decision making. We report two patients with widespread aggressive gliomas whose tumors were found to express the BRAFV600E mutation and then responded robustly albeit transiently when exposed to vemurafenib. Although both patients succumbed to their disease, our results suggest that targeting BRAF might be appropriate for patients with aggressive gliomas that express this mutation.
- 26 January 2013
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 112 (1) , 91-97
The incidence and significance of multiple lesions in glioblastoma
The location and distribution of glioblastoma (GBM) within the brain parenchyma plays an important role in surgical and radiation planning. Prior studies have reported incidences of multiple lesions at the time of diagnosis ranging from 0.5 to 20 %. Multiple lesions can be further categorized as multifocal (multiple areas involved, but with a clear path of spread from one lesion to another) or multicentric (multiple lesions, no clear path of spread). In this retrospective study, we reviewed our experience with GBM and found the incidence of multiple lesions at time of diagnosis was 35 %, much higher than previously suggested in the literature. Patients with single lesions had an improved overall survival when compared to patients with multiple lesions (18 vs. 10 months). Patients with multicentric lesions fared the worst, with average survival of 3 months. However, the difference between single and multiple lesions (multifocal or multicentric) was no longer significant when taking into consideration age, Karnofsky performance score (KPS) and extent of resection by multivariate analysis. Age, KPS, gross total resection, and MGMT status were independent predictors of outcome. Multiple lesions did not independently confer a worse outcome, but were associated with lower KPS scores and inability to perform gross total resection. These findings suggest that single, multiple and multicentric imaging exams represent a spectrum of presentations of a single disease. The rate of multiple lesions reported here may be the result of improved imaging technology, suggesting that incidence of multiple lesions will continue to increase as imaging technology advances.
- 26 January 2013
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 112 (1) , 91-97
The incidence and significance of multiple lesions in glioblastoma
The location and distribution of glioblastoma (GBM) within the brain parenchyma plays an important role in surgical and radiation planning. Prior studies have reported incidences of multiple lesions at the time of diagnosis ranging from 0.5 to 20 %. Multiple lesions can be further categorized as multifocal (multiple areas involved, but with a clear path of spread from one lesion to another) or multicentric (multiple lesions, no clear path of spread). In this retrospective study, we reviewed our experience with GBM and found the incidence of multiple lesions at time of diagnosis was 35 %, much higher than previously suggested in the literature. Patients with single lesions had an improved overall survival when compared to patients with multiple lesions (18 vs. 10 months). Patients with multicentric lesions fared the worst, with average survival of 3 months. However, the difference between single and multiple lesions (multifocal or multicentric) was no longer significant when taking into consideration age, Karnofsky performance score (KPS) and extent of resection by multivariate analysis. Age, KPS, gross total resection, and MGMT status were independent predictors of outcome. Multiple lesions did not independently confer a worse outcome, but were associated with lower KPS scores and inability to perform gross total resection. These findings suggest that single, multiple and multicentric imaging exams represent a spectrum of presentations of a single disease. The rate of multiple lesions reported here may be the result of improved imaging technology, suggesting that incidence of multiple lesions will continue to increase as imaging technology advances.